Vaccine and Immune Globulin Availability

Current Situation
Updated: November 4, 2019

Supply is limited for one rabies vaccine and one rabies immune globulin product. Healthcare providers should continue to administer pre-exposure and post-exposure prophylaxis (PEP) when indicated without any change in practice.


Rabies Vaccine

  • RabAvertexternal icon rabies vaccine (produced by GlaxoSmithKline) is experiencing a temporary limited supply, but is still available for both preexposure prophylaxis (PrEP) and postexposure prophylaxis (PEP). Clinicians can request RabAvert for any patient who needs PrEP or PEP by contacting GSK’s Vaccine Service Center directly at 866-475-8222, option 3.
  • IMOVAXexternal icon rabies vaccine (produced by Sanofi Pasteur) is now available, following a shortage earlier this year. Sanofi Pasteur began shipping IMOVAX on October 28, 2019. IMOVAX is available from wholesalers, distributors and directly from the manufacturer. Call Sanofi Pasteur at 1-800-VACCINE if IMOVAX is not available from your wholesalers or distributors.

Human Rabies Immune Globulin

  • KEDRABexternal icon (produced by Kedrion Biopharma) is available with no restrictions.
  • HyperRabexternal icon (produced by Grifols) is available with no restrictions. (HyperRab® is a more potent version of the previously licensed HyperRab™ S/Dexternal icon and requires a smaller volume to achieve the recommended 20 IU/kg dose.)
  • Imogamexternal icon (produced by Sanofi Pasteur) is currently experiencing a temporary shortage and is only available to healthcare providers who have a patient with current suspected rabies exposure requiring immediate PEP. Providers can obtain Imogam directly from the manufacturer by faxing a completed Rabies Post-Exposure Form found at vaccineshoppe.comexternal icon to 1-877-287-9391 (Attn: Sanofi Pasteur Customer Service).

CDC continues to work with partners to monitor the status of rabies biologic supplies. The current shortage is not expected to impact overall availability of PEP nationally. Healthcare providers should continue to administer PrEP and PEP when indicated. Additional updates will be posted to this page as available.

*Note: HyperRab®external icon immunoglobulin product has a different concentration compared to all other rabies immunoglobulin products (including the very similarly named HyperRab™external icon S/D) and requires lower volumes to administer the recommended dose of 20 IU/kg. Care should be taken to ensure the correct dose of immunoglobulin is administered to ensure adequate immune response.

Recommended Preventive Measures Unaffected by Supply Restriction
  • Standard rabies exposure prevention messaging should be reinforced.
    • Pets and livestock should be vaccinated against rabies as recommended.
    • When possible, after an exposure, efforts should be made to safely capture the animal involved in the exposure and it should be held for observation (if a cat, dog, or ferret) or tested for rabies.
  • Health providers should consult with local/state public health departments to ensure appropriate use of PEP. See: State and local rabies consultation contacts
  • Persons at increased risk for rabies exposure should take appropriate precautions to avoid exposure and consider rabies pre-exposure prophylaxis according to ACIP recommendations.
Disclaimer

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.